Bridgeway Capital Management, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Bridgeway Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$680.49 - $826.97 $1.84 Million - $2.23 Million	-2,700 Reduced 50.94%	2,600 $2.14 Million
Q4 2022 Feb 14, 2023	SELL	$705.89 - $766.39 $3.53 Million - $3.83 Million	-5,000 Reduced 48.54%	5,300 $3.82 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $3.33 Million - $4.2 Million	-5,800 Reduced 36.02%	10,300 $7.1 Million
Q2 2022 Aug 15, 2022	BUY	$548.35 - $738.84 $1.43 Million - $1.92 Million	2,600 Added 19.26%	16,100 $9.52 Million
Q1 2022 May 16, 2022	BUY	$595.12 - $698.43 $8.03 Million - $9.43 Million	13,500 New	13,500 $9.43 Million
Q1 2021 May 17, 2021	SELL	$446.73 - $548.2 $1.72 Million - $2.11 Million	-3,840 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$478.3 - $607.98 $19,132 - $24,319	-40 Reduced 1.03%	3,840 $1.86 Million
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $20.2 Million - $24.4 Million	-37,020 Reduced 90.51%	3,880 $2.17 Million
Q2 2020 Aug 31, 2020	BUY	$493.32 - $643.92 $394,656 - $515,135	800 Added 2.0%	40,900 $25.5 Million
Q2 2020 Aug 14, 2020	BUY	$493.32 - $643.92 $19.8 Million - $25.8 Million	40,100 New	40,100 $25 Million

1,484

83.7M

1.22M

1.5M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.